We are live on ! Find out more
BRA

Bender Robert & Associates Portfolio holdings

AUM $481M
1-Year Est. Return 35.73%
This Fund
S&P 500
This Quarter Est. Return
-22.5%
1 Year Est. Return
+35.73%
3 Year Est. Return
+116.09%
5 Year Est. Return
+167.64%
10 Year Est. Return
+1,066.43%
AUM
$262M
AUM Growth
-$89.5M
Cap. Flow
-$2.38M
Cap. Flow %
-0.91%
Top 10 Hldgs %
66.42%
Holding
56
New
11
Increased
4
Reduced
32
Closed
1

Top Buys

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$708K
2
EOLS icon
Evolus
EOLS
+$296K
3
URGN icon
UroGen Pharma
URGN
+$282K
4
V icon
Visa
V
+$231K
5
AEP icon
American Electric Power
AEP
+$213K

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$622K
2
AMZN icon
Amazon
AMZN
+$497K
3
MELI icon
Mercado Libre
MELI
+$333K
4
IDXX icon
Idexx Laboratories
IDXX
+$268K
5
GOOG icon
Alphabet (Google) Class C
GOOG
+$250K

Sector Composition

Rank Sector Weight
1 Technology 38.9%
2 Consumer Discretionary 25.33%
3 Healthcare 21.63%
4 Communication Services 11.08%
5 Utilities 1.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
26
Gilead Sciences
GILD
$181B
$2.32M 0.89%
37,600
-2,107
-5% -$130K
BMY icon
27
Bristol-Myers Squibb
BMY
$131B
$1.93M 0.74%
25,062
-300
-1% -$22.8K
AMD icon
28
Advanced Micro Devices
AMD
$809B
$1.48M 0.56%
19,288
+1,355
+8% +$127K
CTSH icon
29
Cognizant
CTSH
$28.8B
$1.27M 0.49%
18,898
-465
-2% -$35.6K
PFE icon
30
Pfizer
PFE
$158B
$1.01M 0.38%
19,180
– –
ABT icon
31
Abbott
ABT
$178B
$946K 0.36%
8,706
-35
-0.4% -$3.98K
JNJ icon
32
Johnson & Johnson
JNJ
$644B
$907K 0.35%
5,107
– –
COST icon
33
Costco
COST
$408B
$902K 0.34%
1,883
– –
PAYX icon
34
Paychex
PAYX
$42.2B
$826K 0.32%
7,250
– –
NSC icon
35
Norfolk Southern
NSC
$72B
$782K 0.3%
3,441
-345
-9% -$84.7K
BCRX icon
36
BioCryst Pharmaceuticals
BCRX
$2.1B
$726K 0.28%
+68,600
New +$708K
MRK icon
37
Merck
MRK
$358B
$703K 0.27%
7,712
– –
DE icon
38
Deere & Co
DE
$183B
$467K 0.18%
1,561
– –
JPM icon
39
JPMorgan Chase
JPM
$928B
$466K 0.18%
4,134
-220
-5% -$27.3K
NUE icon
40
Nucor
NUE
$57.8B
$440K 0.17%
4,215
– –
BA icon
41
Boeing
BA
$166B
$402K 0.15%
2,940
-483
-14% -$71.3K
URGN icon
42
UroGen Pharma
URGN
$2.1B
$337K 0.13%
+41,131
New +$282K
TGT icon
43
Target
TGT
$72.3B
$297K 0.11%
2,100
-140
-6% -$26.8K
EOLS icon
44
Evolus
EOLS
$531M
$291K 0.11%
+25,070
New +$296K
CAT icon
45
Caterpillar
CAT
$361B
$289K 0.11%
1,617
-55
-3% -$11.6K
DUK icon
46
Duke Energy
DUK
$92.8B
$282K 0.11%
2,626
– –
TROW icon
47
T. Rowe Price
TROW
$22.6B
$243K 0.09%
2,135
-300
-12% -$38.1K
V icon
48
Visa
V
$700B
$221K 0.08%
+1,120
New +$231K
AEP icon
49
American Electric Power
AEP
$66.7B
$206K 0.08%
+2,150
New +$213K
BBIG
50
DELISTED
Vinco Ventures, Inc. Common Stock
BBIG
$110K 0.04%
+4,000
New +$134K
1
2
3

Similar funds

MA
Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $481M AUM 22.61% 1-Year Est. Return
SA
Stewardship Advisors Mount Joy, Pennsylvania $481M AUM 18.41% 1-Year Est. Return
NC
NovaPoint Capital Atlanta, Georgia $481M AUM 32.01% 1-Year Est. Return
HWMG
Hurlow Wealth Management Group Bloomington, Indiana $481M AUM 20.5% 1-Year Est. Return
MAV
Mason & Associates (Virginia) Newport News, Virginia $481M AUM 12.85% 1-Year Est. Return
OMIC
Old Mission Investment Co Traverse City, Michigan $481M AUM
SCA
Sage Capital Advisors Sioux Falls, South Dakota $482M AUM 34.73% 1-Year Est. Return

Bender Robert & Associates's Q2 2022 Portfolio in Review

As of Q2 2022, Bender Robert & Associates held 56 positions worth $262M, down 26% from $351M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Bender Robert & Associates's Q2 2022 filing shows 11 new, 4 increased, 32 reduced and 1 closed positions. Its largest new stake was BioCryst Pharmaceuticals: 68,600 shares worth $726K. The largest sale was Apple, an estimated $622K.

By sector, the portfolio is most concentrated in Technology at 39% of assets, up from 39% a quarter earlier, followed by Consumer Discretionary and Healthcare.

  • Bender Robert & Associates's largest Q2 2022 buy was BioCryst Pharmaceuticals: 68,600 shares worth $726K.
  • Bender Robert & Associates added most to Advanced Micro Devices in Q2 2022, an estimated $127K increase.
  • Bender Robert & Associates's biggest Q2 2022 reduction was Apple, cutting an estimated $622K.
  • Bender Robert & Associates fully exited Idexx Laboratories in Q2 2022, selling an estimated $268K.
  • Bender Robert & Associates's ten largest holdings make up 66% of its $262M portfolio in Q2 2022.
  • Bender Robert & Associates opened 11 new positions and closed 1 in Q2 2022.
  • Bender Robert & Associates's portfolio value fell 26% quarter-over-quarter to $262M.

Based on Bender Robert & Associates's 13F filing for Q2 2022, filed 19 Jul 2022.